Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect

Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous coronary intervention (PCI) or if the patient can be treated with medical therapy and avoid a permanent metallic stent implant. There were several FFR late-breaking clinical trials presented at the 2020 Transcatheter Cardiovascular Therapeutics (TCT) meeting in October. 
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials presented at the 2020 Transcatheter Cardiovascular Therapeutics (TCT) meeting in October.
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe.
Proportion of gadolinium-based contrast agent (GBCA) subtypes and molecular structure used for cardiac MRI in the European Society of Cardiovascular Radiology MR/CT Registry. A, Use of GBCA subtypes. B, Use of macrocyclic versus linear GBCA

October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very low risk of allergic reactions, vomiting and other acute adverse events, according to a large study from Europe published in Radiology: Cardiothoracic Imaging.[1] The findings come three years after the European Union enacted new regulations on the contrast agents.

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the Watchman FLX left atrial appendage closure (LAAC) device within a broad population of patients with non-valvular atrial fibrillation (NVAF), including those who are at low-to-moderate risk of bleeding from the use of anticoagulation.

October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Health’s artificial intelligence (AI) technology for ultrasound, Caption AI.

The September-October 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine include links to videos, comparison charts and related content.

Free access to the digital issue

Sign up for a free subscription.

 

Content in this issue includes or links to the following:

Chest X-ray, posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

October 27, 2020 – Magnetic resonance imaging (MRI) examinations can be safely performed in patients with non-MR compatible cardiac devices, including pacemakers, abandoned pacing leads, and implantable cardioverter defibrillators (ICDs), according to a new study published in Radiology: Cardiothoracic Imaging.[1]
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.

October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world pulmonary embolism (PE) population, using the FlowTriever thrombectomy device from Inari Medical Inc. The FLASH Registry included high- and intermediate-risk patients, was obtained across 19 U.S. sites. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now